he Rehabilitation of Pain Syndromes (CRPS) at UCLA Medical Center, Los Angeles, CA; and Robert Levy, MD, PhD, Northwestern, University, Feinberg School of Medicine, Chicago, IL. The results were presented during the North American Neuromodulation Society Annual Meeting, Dec. 8-11, in Las Vegas, NV.
"The importance of selecting the best drug options for intraspinal drug delivery to treat those in severe pain cannot be understated," added Deer. "We must continue to keep all our colleagues informed of the best treatment practices in pain management and routinely evaluate treatments and patient data. Best clinical practices, experience, data and overall better patient outcomes will remain at the core of the Polyanalgesic Consensus Conference."
About the 2011 Polyanalgesic Consensus Conference
The PACC is an expert panel of leading pain management physicians from throughout the United States who meet periodically to evaluate the efficiency of various treatments. The panel is supported by an unrestricted medical education grant. Members of the 2011 Panel Include:
Christopher Bernards, MD
Virginia Mason Medical Center,
Seattle, WA
Allen Burton, MD
Houston Pain Associates,
Houston, TX
Eric Buchser, MD
Center for Neuromodulation EHC,
Morges, Switzerland
David Caraway, MD, PhD
Center for Pain Relief
Charleston, WV
Michael Cousins, MD
Royal North Shore Hospital
Sydney, Australia
Jose DeAndres, MD, PhD, FIPP, EDRA
Valencia University General Hospital
Valencia, Spain
Sudhir Diwan, MD, MS
Cornell Weill
New York, NY
Stuart DuPen, MD
Overlake Medical Center Pain Management Clinic
Bellevue, WA
Michael A. Erdeck, MD
Johns Hopkins University
Baltimore, MD
Eric Grigsby, MD
Napa Pain Institute
Napa, CA
Marc A. Huntoon, MD
Vanderbilt University Medical Center
Nashville, TN
Philip S. Kim,
'/>"/>
SOURCE Azur Pharma, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related medicine technology :1.
Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use2.
Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations3.
Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer4.
Boston Scientific Second Quarter Results Exceed Consensus Sales and EPS; Full-Year Guidance Raised5.
Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity6.
TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache7.
Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity8.
TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel9.
Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill10.
Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill11.
Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego